Ignite Creation Date:
2025-12-24 @ 2:44 PM
Ignite Modification Date:
2025-12-27 @ 10:09 AM
Study NCT ID:
NCT04034459
Status:
UNKNOWN
Last Update Posted:
2023-11-14
First Post:
2017-12-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC
Sponsor:
Ludwig-Maximilians - University of Munich
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-11-25
Start Date Type:
ACTUAL
Primary Completion Date:
2023-11-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2017-12-22
First Submit QC Date:
None
Study First Post Date:
2019-07-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-13
Last Update Post Date:
2023-11-14
Last Update Post Date Type:
ACTUAL